Integrum Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Integrum yıllık ortalama 23.4% oranında kazançlarını artırırken, Medical Equipment sektöründe kazançlar declining at 1.1% annual. Gelirler yılda ortalama 30.8% oranında büyüyor .

Anahtar bilgiler

23.4%

Kazanç büyüme oranı

30.0%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	4.3%
Gelir büyüme oranı	30.8%
Özkaynak getirisi	-1.3%
Net Marj	-2.2%
Sonraki Kazanç Güncellemesi	04 Dec 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Integrum nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:6Y1 Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Jul 24	110	-2	92
30 Apr 24	110	4	88
31 Jan 24	101	-4	86
31 Oct 23	87	-19	85
31 Jul 23	80	-18	88
30 Apr 23	78	-16	85
31 Jan 23	81	-7	84
31 Oct 22	76	7	75
31 Jul 22	66	19	65
30 Apr 22	61	21	55
31 Jan 22	52	16	46
31 Oct 21	49	16	41
31 Jul 21	49	2	39
30 Apr 21	44	-2	35
31 Jan 21	39	-4	35
31 Oct 20	35	-9	36
31 Jul 20	31	-14	36
30 Apr 20	28	-16	38
31 Jan 20	23	-20	41
31 Oct 19	21	-24	44
31 Jul 19	25	-24	45
30 Apr 19	26	-25	46
31 Jan 19	26	-23	44
31 Oct 18	22	-23	40
31 Jul 18	17	-23	37
30 Apr 18	19	-18	34
31 Jan 18	20	-17	33
31 Oct 17	24	-10	31
31 Jul 17	22	-9	28
30 Apr 17	23	-6	26
31 Jan 17	24	0	21
30 Apr 16	18	0	16
30 Apr 15	17	0	14
30 Apr 14	19	2	12

Kaliteli Kazançlar: 6Y1 şu anda kârlı değil.

Büyüyen Kar Marjı: 6Y1 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 6Y1 kârlı değildir, ancak son 5 yılda zararlarını yılda 23.4% oranında azaltmıştır.

Büyüme Hızlandırma: 6Y1 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 6Y1 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 16.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 6Y1 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -1.32% ) sahiptir.

Integrum Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2025 earnings released

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

Recent updates

Inger Rydin Announces Executive Changes

Integrum Announces Change in Chief Executive Officer

First quarter 2025 earnings released

Integrum AB (publ), Annual General Meeting, Sep 25, 2024

Less than half of directors are independent

New minor risk - Shareholder dilution

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

New major risk - Revenue and earnings growth

Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023

Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations

Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations

New minor risk - Profitability

Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing

Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI

Integrum Receives Unitary Patent for Neuromotus in the EU

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum Initiates A Strategic Review Process to Accelerate Growth

Integrum AB Receives Reimbursement Code for Axor II

Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand

Integrum AB (Publ) Announces Management Changes

New major risk - Share price stability

Full year 2023 earnings released

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Third quarter 2023 earnings released

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Second quarter 2023 earnings released

Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and Neuromotus

Less than half of directors are independent

Investor sentiment improved over the past week

Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade Organization

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2023 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released

Integrum AB (publ) to Report Q1, 2023 Results on Sep 02, 2022

Integrum AB (publ) Announces Board Changes

Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical Officer

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Forecast to breakeven in 2023

First quarter 2022 earnings released

Full year 2021 earnings released: kr0.038 loss per share (vs kr1.04 loss in FY 2020)

Art Clinic, Center of Excellence in the Nordic countries, has treated its first patient with Integrum's OPRA™ Implant System

Third quarter 2021 earnings released

BG Klinik Tübingen to Treat Thumb Amputees with Integrum's OPRA Implant System

Integrum AB Collaboration with Onkos Pave the Way for Further Growth in the US

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi